In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
15 authors.
Anirban GhoshalStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-9359-6074 John D SearsDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID 0000-0002-4713-2241 Mohammad Anwar HossainStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-8684-8755 Edwin G TseStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-9133-9274 Stefanie HowellStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3392-2848 Jane E BurdickREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0009-0001-9719-8302 Noah L MoralesREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0009-0003-2965-477X Sabian A MartinezREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-1333-5083 Isabella LawREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0009-0001-6845-1284 Zachary J StreblowREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0009-0002-3338-4867 Daniel N StreblowREADDI AViDD Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-6828-2492 Rafael Miguez CouñagoStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-1847-5090 Nathaniel J MoormanDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID 0009-0008-6391-3268 Mark T HeiseDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.ORCID 0000-0001-5829-8477 Timothy M WillsonStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-4181-8223 Funding
Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WILLSON, TIMOTHY M · 2022 to 2022
$65.5MRequest for a 500 MHz NMR console and nitrogen-cooled cryoprobeS10OD032476 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEE, ANDREW L · 2022 to 2022
$599kNIAID NIH HHS U19 AI171292NIH HHS S10 OD032476
6 · The paper itselfAbstract
The emergence of mosquito-borne alphaviruses that cause chronic arthritis or encephalitis underscores the urgent need for broad-spectrum antiviral therapeutics. The viral nsP2 cysteine protease, which is essential for alphavirus replication, is a promising antiviral target. Vinyl sulfone-based inhibitors, such as RA-2034, potently inhibit nsP2 protease but suffer from glutathione reactivity and species-dependent systemic clearance catalyzed by glutathione
Indexed as
alphavirusantiviral drug discoverycovalent inhibitorcysteine proteasesulfamate warhead
Identifiers
PMID40631155
PMCPMC12236718
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390